Providers

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 5.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 4.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 3.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 2.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 1.

The top 5 most-watched video interviews of 2021 on AJMC.com addressed myths about COVID-19 vaccination, eye health, and dermatologic conditions, as well as the use of sodium glucose co-transporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes, chronic kidney disease, and heart failure.

The top 5 most-read sleep articles of 2021 on AJMC.com covered emerging therapies in the treatment of obstructive sleep apnea and idiopathic hypersomnia, the effects of antidepressant use on rapid-eye movement sleep, and the sleep-related effects of COVID-19.

A focus group consisting of patients with chronic kidney disease (CKD) as well as CKD providers and researchers shared what they deem necessary and helpful to include in future mobile CKD management applications.

In 2021, there were some changes to recommendations and an important FDA approval for patients with heart failure or who are at risk of heart disease.

Tech-driven connectivity and collaboration tools empower primary care providers (PCPs) to shepherd patient care, while simultaneously empowering patients to make more informed and strategic decisions about their own health and care journey.

Articles on treating and protecting patients with blood cancers from COVID-19 and the positive results of zanubrutinib to treat leukemia and lymphoma were among the most read of the year.

Data from the GLOW study of minimal residual disease evaluation following chemotherapy for chronic lymphocytic leukemia (CLL) show the kinase inhibitor/B-cell lymphoma-2 inhibitor pair produced superior outcomes compared with the alkylating agent/monoclonal antibody combination.

Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor of neurology, Albert Einstein College of Medicine, discusses treatment implications for clinicians managing chronic insomnia and potential comorbid conditions.

Epigenetics has a role in choosing the right medicine in lung cancer, artificial intelligence can predict outcomes in a highly aggressive cancer, and more.

A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.

Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, explains why patients provided sodium-glucose co-transporter 2 (SGLT2) inhibitors in hospitals may be unable to continue the medication after discharge.

Facing the challenges created by the COVID-19 pandemic, the US medical community has been forced to rapidly change and modernize the manner in which it delivers health care over the last year-and-a-half. 

Key opinion leaders discuss the state of mental health in the US workforce, persistent unmet needs, and efforts to improve coverage and uptake of behavioral health services.

Although the pandemic continued to rule health care headlines, a few other stories were noteworthy in 2021 for the AJMC.com audience, including articles about a wider indication for the glucagon-like peptide-1 receptor agonist semaglutide and the heart failure drug Entresto.

This year’s most-read articles on pulmonary arterial hypertension (PAH) covered a range of topics, including nutrition, therapy switches, and patient education to improve treatment adherence. Improving patient outcomes is something they all had in common.

Childhood psoriasis was found to be significantly associated with environmental tobacco smoke exposure, whereas intrauterine smoking exposure was not associated with an increased risk in pediatric populations.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.

Two posters presented at The Liver Meeting evaluated nonalcoholic fatty liver disease (NAFLD)–associated hepatocellular carcinoma (HCC) to understand the burden and identify the risk for developing HCC.

This year the United States only approved 2 biosimilars, but the FDA did grant interchangeable status to the first biosimilar.

People experiencing teeth grinding or clenching during sleep, called sleep bruxism, were found to be more likely than the general population to report incidence of other sleep disorders, such as obstructive sleep apnea and restless leg syndrome.